Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors

Published:2019-10-22 Issue:1 Volume:43 Page:58-63
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

He Liru,Liu Yang,Han Hui,Liu Zhuowei,Huang Sijuan,Cao Wufei,Liu Boji,Qin Zike,Guo Shengjie,Zhang Zhiling,Lin Maosheng,Jiang Xiaobo,Lin Chengguang,Li Yonghong,Yao Kai,Dong Pei,Zhou Fangjian

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference32 articles.

1. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007

2. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial;Hutson;Lancet Oncol,2013

3. Pazopanib versus sunitinib in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2013

4. Outcomes for patients with metastatic renal cell carcinoma achieving a complete response on targeted therapy: a registry-based analysis;Buchler;Eur Urol,2016

5. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma;Chapin;Eur Urol,2011

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma;Kidney Cancer;2024-02-16

2. Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma;Current Oncology;2023-12-01

3. Breaking barriers: Stereotactic ablative proton and photon radiation therapy for renal cell carcinoma with extensive metastases: A case report;Medical Dosimetry;2023-08

4. Beyond the Knife in Renal Cell Carcinoma: A Systematic Review—To Ablate or Not to Ablate?;Cancers;2023-06-30

5. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium;The Lancet Oncology;2023-03